Results 151 to 160 of about 198,084 (294)

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

open access: yesBrain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles   +15 more
wiley   +1 more source

Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes

open access: yesBrain Pathology, EarlyView.
In this study including 31 circumscribed meningeal melanocytic neoplasms (melanocytoma, intermediate‐grade melanocytic tumor [IMT], and melanoma), overall survival (OS) differed significantly among the groups, with melanoma showing significantly worse OS than melanocytoma and IMT showing intermediate OS between melanocytoma and melanoma.
Yi Zhu   +12 more
wiley   +1 more source

TRIM59 Drives Bladder Cancer Progression Through E3 Ligase‐Dependent K48‐Linked Degradation of PTRF

open access: yesCancer Science, EarlyView.
Schematic model of TRIM59‐driven BLCA progression through K48‐linked ubiquitination and proteasomal degradation of PTRF, leading to AKT activation and c‐Myc upregulation. ABSTRACT Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood ...
Junlin Gan   +9 more
wiley   +1 more source

Pathogenicity of NUSAP1 Variants Is Defined by NMD‐Escape: Evidence From Two Novel Cases and Systematic Population‐Based Variant Analysis

open access: yesClinical Genetics, EarlyView.
Heterozygous de novo nonsense variants in the penultimate and last exons of NUSAP1 were identified in two unrelated individuals, predicted to escape NMD. In population data, nonsense variants were observed in exons 1–9 (of 11) in NUSAP1 but were absent from its 3′‐terminal region.
Maureen Jacob   +15 more
wiley   +1 more source

Ploidy‐Dependent Response to Anticancer Drugs of Human Embryonic Stem Cells

open access: yesCell Proliferation, EarlyView.
Using isogenic hESCs, differing only in their ploidy level, we show the effect of ploidy on the resistance to anticancer drugs. We demonstrate that polyploidy, by itself, confers sensitivity to chemotherapies, leading to higher apoptosis and delayed proliferation, while the loss of p53 reverses the phenotype, demonstrating higher resistance.
Guy Haim‐Abadi, Nissim Benvenisty
wiley   +1 more source

A 67‐year‐old man with a spinal extramedullary mass

open access: yes
Brain Pathology, EarlyView.
Marcella Callea   +3 more
wiley   +1 more source

Merkel Cell Carcinoma With Divergent Differentiation—Or Something Else? A Triphasic Cutaneous Carcinoma With Lineage Plasticity

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma that typically arises in sun‐exposed skin of older or immunosuppressed patients. Combined or collision tumors involving MCC and other cutaneous malignancies are uncommon, and tumors exhibiting more than two distinct malignant phenotypes are exceptionally rare.
Zeinab Khalil   +2 more
wiley   +1 more source

TIGAR Maintains Mitotic Spindle Organization and βII-Tubulin Stability in Glioma Stem Cells. [PDF]

open access: yesCNS Neurosci Ther
Chen A   +8 more
europepmc   +1 more source

Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Introduction Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry helps distinguish non‐acral melanocytic lesions, but few studies have addressed its value in acral lesions. We aimed to identify an optimal PRAME cut‐off score to differentiate acral melanoma (AM) from acral melanocytic nevi (AMN).
Kritsada Phatcharamaneepakorn   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy